InMed Pharmaceuticals Inc (INM) - Total Assets
Based on the latest financial reports, InMed Pharmaceuticals Inc (INM) holds total assets worth $9.13 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check how aggressively does InMed Pharmaceuticals Inc reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
InMed Pharmaceuticals Inc - Total Assets Trend (2001–2025)
This chart illustrates how InMed Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. Check INM cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
InMed Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (June 2025)
InMed Pharmaceuticals Inc's total assets of $9.13 Billion consist of 82.6% current assets and 17.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 71.1% |
| Accounts Receivable | $633.67K | 3.0% |
| Inventory | $1.31 Million | 6.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $2.21 Million | 10.4% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2001–2025)
This chart illustrates how InMed Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is InMed Pharmaceuticals Inc worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: InMed Pharmaceuticals Inc's current assets represent 82.6% of total assets in 2025, an increase from 50.8% in 2001.
- Cash Position: Cash and equivalents constituted 71.1% of total assets in 2025, up from 0.9% in 2001.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 10.0% of total assets, an increase from 0.0% in 2001.
- Asset Diversification: The largest asset category is intangible assets at 10.4% of total assets.
InMed Pharmaceuticals Inc Competitors by Total Assets
Key competitors of InMed Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA
|
India | Rs585.02 Billion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026
|
China | CN¥10.37 Billion |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099
|
China | CN¥7.28 Billion |
|
Xeris Pharmaceuticals Inc
NASDAQ:XERS
|
USA | $392.01 Million |
|
Procter & Gamble Health Limited
NSE:PGHL
|
India | Rs8.94 Billion |
InMed Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.11 | 3.49 | 3.78 |
| Quick Ratio | 3.11 | 3.04 | 3.78 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $4.68 Billion | $6.51 Million | $7.62 Million |
InMed Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between InMed Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.24 |
| Latest Market Cap to Assets Ratio | 0.10 |
| Asset Growth Rate (YoY) | 31.3% |
| Total Assets | $21.23 Million |
| Market Capitalization | $2.06 Million USD |
Valuation Analysis
Below Book Valuation: The market values InMed Pharmaceuticals Inc's assets below their book value (0.10x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: InMed Pharmaceuticals Inc's assets grew by 31.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for InMed Pharmaceuticals Inc (2001–2025)
The table below shows the annual total assets of InMed Pharmaceuticals Inc from 2001 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | $21.23 Million | +31.28% |
| 2024-06-30 | $16.17 Million | -13.48% |
| 2023-06-30 | $18.69 Million | +13.50% |
| 2022-06-30 | $16.46 Million | +36.11% |
| 2021-06-30 | $12.10 Million | +55.04% |
| 2020-06-30 | $7.80 Million | -48.24% |
| 2019-06-30 | $15.07 Million | -29.36% |
| 2018-06-30 | $21.34 Million | +232.90% |
| 2017-06-30 | $6.41 Million | +402.07% |
| 2016-06-30 | $1.28 Million | -4.59% |
| 2015-06-30 | $1.34 Million | -15.84% |
| 2014-06-30 | $1.59 Million | +31111.50% |
| 2013-06-30 | $5.09K | -89.23% |
| 2012-06-30 | $47.31K | -80.96% |
| 2011-06-30 | $248.50K | +80.74% |
| 2010-06-30 | $137.49K | +440.85% |
| 2009-06-30 | $25.42K | -98.16% |
| 2008-06-30 | $1.38 Million | +242.49% |
| 2007-06-30 | $403.26K | -38.12% |
| 2006-06-30 | $651.70K | -33.82% |
| 2005-06-30 | $984.74K | +80.39% |
| 2004-06-30 | $545.89K | -53.10% |
| 2003-06-30 | $1.16 Million | -14.61% |
| 2002-06-30 | $1.36 Million | -70.83% |
| 2001-06-30 | $4.67 Million | -- |
About InMed Pharmaceuticals Inc
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. The company operates through two segments, InMed Pharmaceuticals and BayMedica Commercial. The InMed Pharmaceuticals segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufactur… Read more